{"id":20049,"date":"2023-09-13T07:39:20","date_gmt":"2023-09-13T07:39:20","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20049"},"modified":"2023-09-13T07:39:20","modified_gmt":"2023-09-13T07:39:20","slug":"ers-genomics-grants-transomic-access-to-crispr-cas9-portfolio","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/ers-genomics-grants-transomic-access-to-crispr-cas9-portfolio\/","title":{"rendered":"ERS Genomics grants Transomic access to CRISPR\/Cas9 portfolio"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

ERS Genomics grants Transomic access to CRISPR\/Cas9 portfolio<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR\/Cas9 patent portfolio.<\/h3>\n

<\/p>\n

Dr Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR\/Cas9. As a direct outcome, the ERS patent portfolio stands as the definitive collection of proprietary rights to this gene editing technology.<\/p>\n

Founded in 2012, Transomic’s mission is to equip life science researchers with cutting-edge gene modulation tools derived from the forefront of biotechnology advancements. Specializing in molecular cloning, their portfolio of products and services revolves around vector-based solutions.<\/p>\n

Commenting on the agreement with ERS, Blake Simmons, CEO, Transomic Technologies, said: \u201cTransomic recognizes the extremely valuable role that gene-editing technology plays in life science research and drug discovery.
\n“We are very excited to be able to continue to expand our CRISPR\/Cas9 research tool business by licensing this important patent portfolio from ERS genomics.\u201d<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Blake Simmons, CEO, <\/em>
\nTransomic\u00a0Technologies<\/em><\/p>\n<\/div><\/section>
\n